Opportunities
Search

Buyer: Waterschap Hunze en Aa's | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-01

Buyer: European Union Agency for the Space Programme | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-01

Buyer: Christelijke Hogeschool Windesheim | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-01

Buyer: Aeres | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-01

Buyer: Thuispunt Gent bv | Notice type: cn-standard | Procedure: neg-w-call | Contract: works | Deadline: 2026-09-01

Buyer: Thuispunt Gent bv | Notice type: cn-standard | Procedure: neg-w-call | Contract: works | Deadline: 2026-09-01

Buyer: Land Niederösterreich, p.A. Amt der NÖ Landesregierung, Gruppe Straße - ST5 Brückenbau | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-01

Buyer: VILLE DE NICE | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-01

Buyer: Ministerie van Defensie | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-01

Buyer: Technische Universiteit Delft | Notice type: pin-rtl | Procedure: restricted | Contract: services | Deadline: 2026-09-01

Buyer: AOK - Die Gesundheitskasse in Hessen Postanschrift: Kölner Str. 8, 65760 Eschborn Land: Deutschland Kontaktstelle(n): z. Hd. Frau Corinna Varelmann E-Mail: am-vertragsteam@he.aok.de Telefon: +49 61964069711 Fax: +49 6966816559711 Internet-Adresse(n):Hauptadresse: http://www.aok.de/hessen/ | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-01

Buyer: AOK NordWest | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-01

Buyer: AOK NordWest | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-01

Buyer: AOK Nordost - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-01

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Award (PCOSA) promotes evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research must address at least one of the FY26 LCRP areas of emphasis in the Health Outcomes and Survivorship category.Distinctive Features:• This funding mechanism requires the research team to include an advocate who is a lung cancer patient/survivor or caregiver.• This funding mechanism allows proposed projects to include translational or clinical research, including pilot clinical trials.

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.Distinctive Features: This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions.

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis.Distinctive Features: This FY26 LCRP IDA mechanism has a New Investigator category that is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Data Science Award (DSA) supports research that develops or uses quantitative and analytical approaches, processes and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in one or more of the following research areas: Analysis of clinically annotated datasets; analysis of -omics data; artificial intelligence and machine learning; bioinformatics; computational biology; digital pathology; epidemiology; and medical imaging. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (EIRA) supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced mentor. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        Early-Career Investigator: Serves as the principal investigator. Includes investigators possessing a doctoral degree or equivalent with fewer than three years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training. ·        Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship. ·        Researcher Development Plan: Applications must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the Principal Investigator’s (PI’s) career development

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        New Investigator Category: In addition to established investigators, the FY26 PCRP Idea Development Award encourages research ideas from investigators in the early stages of their careers (i.e., within 10 years after completion of their terminal degree). Qualified new investigators must identify a collaborator(s) experienced in prostate cancer research.   https://cdmrp.health.mil/pubs/press/2026/pcrppreann

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        Early-Career Clinician Investigator: Serves as the Principal Investigator (PI). Includes investigators with clinical duties in the last year of an accredited medical residency or medical fellowship program, or within five years of initiating a faculty appointment. ·        Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship. ·        Researcher Development Plan: Applications must include a research development plan articulating an individualized strategy for acquiring necessary skills, competence and expertise to complete the projects and foster the PI’s career development. https://cdmrp.health.mil/pubs/press/2026/pcrppreann

Objective:1. BackgroundThe EDCTP Prizes 2026-2027 are recognition prizes funded under Horizon Europe.Prizes are financial contributions given as rewards following the publication of a contest. A ‘recognition prize’ is used to recognise past achievements and outstanding work after it has been performed, whereas an ‘inducement prize’ is used to spur investment in a given direction, by specifying a target prior to the performance of the work.Applications will have to clearly state the involvement of the applicants in the research and innovation activities within the remit of the Global Health EDCTP3 programme. Applicants will have to provide proof of eligibility and a written presentation of the achievements, which will be presented to an independent panel of experts for evaluation.The amounts of the prizes are specified in section 3. They are not linked to the costs incurred by the winner....

Expected Outcome:Actions funded under this Call are expected to contribute to: Increased participation of under-represented groups in entrepreneurial activities; Improved access to tailored incubation services and financing opportunities for aspiring entrepreneurs facing structural barriers; Enhanced entrepreneurial skills, business readiness and sustainability of supported enterprises; Strengthened cooperation between incubation providers, financial actors and employment or social inclusion stakeholders; Development of innovative, evidence-based approaches, as a possible source of inspiration for other initiatives; Improved knowledge and policy learning regarding effective inclusive entrepreneurship support mechanisms. In the longer term, the Call is expected to contribute to more inclusive labour markets, job creation, strengthened social economy ecosystems and reduced inequalities in...

Objective:1. BackgroundThe EDCTP Prizes 2026-2027 are recognition prizes funded under Horizon Europe.Prizes are financial contributions given as rewards following the publication of a contest. A ‘recognition prize’ is used to recognise past achievements and outstanding work after it has been performed, whereas an ‘inducement prize’ is used to spur investment in a given direction, by specifying a target prior to the performance of the work.Applications will have to clearly state the involvement of the applicants in the research and innovation activities within the remit of the Global Health EDCTP3 programme. Applicants will have to provide proof of eligibility and a written presentation of the achievements, which will be presented to an independent panel of experts for evaluation.The amounts of the prizes are specified in section 3. They are not linked to the costs incurred by the winner....

Expected Outcome:Objectives and profile of the ERC Plus Grant Principal InvestigatorThe ERC Plus Grant supports outstanding Principal Investigators who address a major scientific challenge. Applications for ERC Plus Grants should be for projects that could not be carried out with a regular ERC grant. Applicants should explain how the proposed project aims go beyond those of a regular ERC project, for example, because they have a vision to transform their field or open a new field of research. Scholars at all career stages can apply for an ERC Plus Grant if they have an outstanding record of scientific achievement at the forefront of their field. Their intellectual leadership will be evaluated in comparison to peers at their own career stage.It is expected that a researcher may be the Principal Investigator of only one ERC Plus Grant in their lifetime. Applicants should be aware that ever...